330MO Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies
Jinhong Zhu(Harbin Medical University), Qiu Li(Macau University of Science and Technology), Aileen Cohen(Düsseldorf University Hospital), Constantine S. Tam(The Alfred Hospital), Hongyan Guo(Qingdao Agricultural University), Hongyu Zhou(Sichuan University), Puja Khanna(University of Michigan), W.S. Kim(Samsung Medical Center), Jing Zhang(Biostat (United States)), Mingjie Zhang(Hong Kong University of Science and Technology), Jingyuan Li(Northwestern University), Lei Wang(Hebei Medical University), Nadia Bahadur
Cited by 0
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Role of BNIP3 and NIX in cell death, autophagy, and mitophagy
|Cell Death and Differentiation|2009|1k